SEMHF
Siemens Healthineers AG
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Sell
-36/100
Last price
43.00
▼ 0.38 (0.86%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
43.00
Prev close
43.37
Day high
44.50
Day low
44.50
Volume
370
Market cap
$48.12B
P/E (TTM)
18.69
52W range
37.00 – 57.75
Day trading desk
Gap from prior close
-0.86%
Prior close 43.37
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
—
43.00 – 43.00
Position in range
—
—
ATR (14D)
1.52
3.53% of price
Prior day high
43.37
PDH
Prior day low
43.37
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 3.91K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-3.92%
-5.8%
1M
-4.54%
-6.0%
3M
+4.87%
+1.5%
6M
-3.77%
-18.7%
YTD
-18.82%
-32.8%
1Y
-24.38%
-40.1%
3Y
-15.90%
-97.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on SEMHF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
747.27M
Total on file
Fundamentals
Market cap$48.12B
Enterprise value$60.65B
Revenue (TTM)$23.17B
Gross profit$9.04B
EBITDA$4.02B
Net income$2.21B
EPS (TTM)$2.30
Free cash flow$2.15B
Total cash$2.36B
Total debt$15.00B
Book value / share$19.93
Shares outstanding1.12B
Float357.71M
Short % of float—
Dividend yield2.77%
Beta (5Y)0.83
Valuation & profitability ratios
Trailing P/E18.69
Forward P/E—
PEG ratio1.77
Price / sales—
Price / book2.16
EV / revenue2.62
EV / EBITDA15.08
Gross margin39.02%
Operating margin16.41%
Profit margin9.55%
Return on equity12.15%
Return on assets4.48%
Debt / equity78.30
Current ratio1.16
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | — | $22.36B | $21.68B | $21.71B | — |
| Operating revenue | — | $22.36B | $21.68B | $21.71B | — |
| Cost of revenue | — | $13.89B | $13.97B | $13.58B | — |
| Gross profit | — | $8.47B | $7.71B | $8.14B | — |
| Research & development | — | $1.92B | $1.87B | $1.78B | — |
| Selling, general & admin | — | $3.68B | $3.61B | $3.41B | — |
| Total operating expense | — | $5.66B | $5.58B | $5.21B | — |
| Operating income | — | $2.81B | $2.13B | $2.92B | — |
| Net interest income | — | -$283.00M | -$207.00M | -$127.00M | — |
| Pre-tax income | — | $2.52B | $1.93B | $2.80B | — |
| Tax provision | — | $564.00M | $403.00M | $746.00M | — |
| Net income | — | $1.94B | $1.51B | $2.04B | — |
| Net income to common | — | $1.94B | $1.51B | $2.04B | — |
| Basic EPS | 1.91 | 1.74 | 1.35 | 1.81 | +9.8% |
| Diluted EPS | 1.91 | 1.73 | 1.34 | 1.81 | +10.4% |
| EBIT | — | $3.00B | $2.22B | $2.92B | — |
| EBITDA | — | $4.22B | $3.78B | $4.26B | — |
| Basic shares | 1.12B | 1.12B | 1.12B | 1.12B | +0.2% |
| Diluted shares | 1.12B | 1.12B | 1.12B | 1.13B | +0.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | — | $2.68B | $2.25B | $1.44B | — |
| Cash & short-term investments | $2.25B | $2.77B | $2.37B | $1.60B | -19.0% |
| Accounts receivable | $4.60B | $4.41B | $4.42B | $4.22B | +4.5% |
| Inventory | $4.09B | $4.14B | $4.26B | $3.97B | -1.4% |
| Total current assets | — | $14.44B | $14.14B | $13.38B | — |
| Property, plant & equipment | $4.71B | $4.47B | $4.21B | $4.27B | +5.4% |
| Goodwill & intangibles | $23.63B | $24.72B | $25.84B | $27.77B | -4.4% |
| Total assets | — | $46.05B | $46.68B | $49.06B | — |
| Total current liabilities | — | $11.57B | $13.44B | $12.02B | — |
| Current debt | $93.00M | $95.00M | $31.00M | $67.00M | -2.1% |
| Long-term debt | — | $0 | $10.00M | $15.00M | — |
| Total debt | $756.00M | $780.00M | $633.00M | $694.00M | -3.1% |
| Total liabilities | — | $27.81B | $28.55B | $29.20B | — |
| Retained earnings | — | $2.15B | $1.38B | $894.00M | — |
| Shareholder equity | — | $18.20B | $18.08B | $19.84B | — |
| Working capital | — | $2.87B | $696.00M | $1.35B | — |
| Net tangible assets | -$5.59B | -$6.53B | -$7.76B | -$7.94B | +14.3% |
| Shares issued | — | 1.13B | 1.13B | 1.13B | — |
| Line item | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|
| Net income | $1.96B | $1.52B | $2.05B | +28.5% |
| Depreciation & amortisation | $1.22B | $1.56B | $1.34B | -21.5% |
| Change in working capital | -$341.00M | -$602.00M | -$831.00M | +43.4% |
| Operating cash flow | $2.83B | $2.12B | $2.50B | +33.4% |
| Capital expenditure | -$696.00M | -$838.00M | -$852.00M | +16.9% |
| Investing cash flow | -$666.00M | -$1.07B | -$868.00M | +37.7% |
| Share buybacks | $0 | -$421.00M | -$309.00M | +100.0% |
| Dividends paid | -$1.06B | -$1.07B | -$955.00M | +0.3% |
| Financing cash flow | -$1.66B | -$730.00M | -$1.64B | -127.0% |
| Free cash flow | $2.13B | $1.28B | $1.65B | +66.3% |
| End cash position | $2.68B | $2.25B | $1.44B | +19.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $5.76B | $5.68B | $5.40B | $5.66B | $5.91B | +1.5% |
| Operating revenue | $5.76B | $5.68B | $5.40B | $5.66B | $5.91B | +1.5% |
| Cost of revenue | $3.31B | $3.54B | $3.33B | $3.48B | $3.59B | -6.4% |
| Gross profit | $2.45B | $2.14B | $2.08B | $2.18B | $2.32B | +14.4% |
| Research & development | $488.00M | $487.00M | $476.00M | $493.00M | $485.00M | +0.2% |
| Selling, general & admin | $1.01B | $963.00M | $925.00M | $947.00M | $991.00M | +4.7% |
| Total operating expense | $1.50B | $1.42B | $1.40B | $1.45B | $1.48B | +6.2% |
| Operating income | $946.00M | $725.00M | $677.00M | $732.00M | $844.00M | +30.5% |
| Net interest income | -$68.00M | -$82.00M | -$74.00M | $4.00M | -$111.00M | +17.1% |
| Pre-tax income | $877.00M | $644.00M | $603.00M | $736.00M | $730.00M | +36.2% |
| Tax provision | $201.00M | $132.00M | $147.00M | $180.00M | $194.00M | +52.3% |
| Net income | $669.00M | $506.00M | $449.00M | $552.00M | $530.00M | +32.2% |
| Net income to common | $669.00M | $506.00M | $449.00M | $552.00M | $530.00M | +32.2% |
| Basic EPS | 0.60 | — | 0.40 | 0.49 | — | — |
| Diluted EPS | 0.60 | — | 0.40 | 0.49 | — | — |
| EBIT | $980.00M | $744.00M | $699.00M | $840.00M | $834.00M | +31.7% |
| EBITDA | $1.28B | $1.00B | $997.00M | $1.21B | $1.15B | +28.1% |
| Basic shares | 1.11B | — | 1.12B | 1.13B | — | — |
| Diluted shares | 1.11B | — | 1.12B | 1.13B | — | — |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $2.36B | $1.91B | $2.14B | — | $2.37B | $2.40B | +23.7% |
| Cash & short-term investments | $2.75B | $2.30B | $2.61B | $2.25B | $2.77B | — | +19.8% |
| Accounts receivable | $4.51B | $4.58B | $4.48B | $4.60B | $4.36B | — | -1.5% |
| Inventory | $4.72B | $4.46B | $4.42B | $4.09B | $4.40B | — | +5.8% |
| Total current assets | $14.96B | $14.18B | $14.19B | — | $14.13B | $14.59B | +5.5% |
| Property, plant & equipment | $4.94B | $4.84B | $4.74B | $4.71B | $4.62B | — | +2.0% |
| Goodwill & intangibles | $23.91B | $23.82B | $23.52B | $23.63B | $23.80B | — | +0.4% |
| Total assets | $45.74B | $44.81B | $44.27B | — | $44.60B | $46.91B | +2.1% |
| Total current liabilities | $12.87B | $12.88B | $13.65B | — | $12.64B | $13.27B | -0.1% |
| Current debt | — | $148.00M | — | $93.00M | — | $111.00M | — |
| Total debt | $746.00M | $821.00M | $764.00M | $756.00M | $735.00M | — | -9.1% |
| Total liabilities | $26.58B | $26.55B | $25.79B | — | $26.88B | $28.19B | +0.1% |
| Retained earnings | $3.75B | $3.05B | $3.68B | — | $2.70B | $2.13B | +23.0% |
| Shareholder equity | $19.10B | $18.21B | $18.43B | — | $17.68B | $18.67B | +4.9% |
| Working capital | $2.08B | $1.29B | $542.00M | — | $1.50B | $1.32B | +61.0% |
| Net tangible assets | -$4.81B | -$5.61B | -$5.09B | -$5.59B | -$6.12B | — | +14.3% |
| Shares issued | 1.12B | 1.13B | 1.13B | — | 1.12B | 1.13B | -0.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | $676.00M | $512.00M | $456.00M | $556.00M | $537.00M | +32.0% |
| Depreciation & amortisation | $305.00M | $259.00M | $298.00M | $370.00M | $312.00M | +17.8% |
| Change in working capital | $177.00M | -$82.00M | -$357.00M | $116.00M | -$403.00M | +315.9% |
| Operating cash flow | $1.23B | $572.00M | $492.00M | $1.03B | $393.00M | +115.6% |
| Capital expenditure | -$210.00M | -$183.00M | -$161.00M | -$191.00M | -$195.00M | -14.8% |
| Investing cash flow | -$198.00M | -$186.00M | -$201.00M | -$191.00M | -$191.00M | -6.5% |
| Share buybacks | -$66.00M | $0 | -$42.00M | -$170.00M | — | — |
| Financing cash flow | -$605.00M | -$640.00M | -$327.00M | -$800.00M | -$549.00M | +5.5% |
| Free cash flow | $1.02B | $389.00M | $331.00M | $844.00M | $198.00M | +163.0% |
| End cash position | $2.36B | $1.91B | $2.14B | $2.37B | $2.40B | +23.7% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $6.72B | +6.4% |
| Next quarter | — | — | $5.68B | +5.1% |
| Current year | — | — | $23.60B | +1.0% |
| Next year | — | — | $25.02B | +6.0% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders67.02%
Held by institutions13.74%
Institutions holding462
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
43.79
-1.80% from price
SMA 20
44.39
-3.14% from price
SMA 50
45.48
-5.46% from price
SMA 100
42.72
+0.65% from price
SMA 200
45.06
-4.57% from price
EMA 12
43.92
-2.09% from price
EMA 26
44.45
-3.27% from price
EMA 50
44.39
-3.13% from price
RSI (14)
41.6
Neutral
MACD (12,26,9)
-0.54
Hist -0.14
ATR (14)
1.52
3.53% of price
Realised vol 30D
29.0%
Annualised
Bollinger upper
46.36
20, 2σ
Bollinger lower
42.43
20, 2σ
50 / 200 cross
Golden
45.48 vs 45.06
Trend bias
Below 200
-4.57%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.45
Less volatile than market
Correlation to SPY
0.14
Largely independent
Realised vol 30D
29.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-34.4%
Peak to trough
Max drawdown 5Y
-40.1%
Peak to trough
ATR 14
1.52
3.53% of price
Beta (reported)
0.83
5Y monthly, from filing
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 23, 21 | Societe Generale | INITIATED | — | Buy |
Dividends & splits
Forward rate$1.19 / yr
Forward yield2.77%
5-year avg yield1.87%
Payout ratio50.76%
Ex-dividend dateFeb 6, 2026
Next pay date—
Last split—
Split date—
Headlines
Medtronic names Felicia Kurz as cardiac ablation VP, GM
MedTech Dive · 10h ago
Artificial Intelligence in Healthcare Market Forecasts Growth from $36.67B (2026) to $194.79B by 2031, Profiling Philips, Microsoft, Siemens Healthineers & NVIDIA
GlobeNewswire · 6d ago
Truvian Health Announces Strategic Alliance with Siemens Healthineers to Advance the TruVerus™ Blood Testing Platform
Business Wire · 7d ago
The Future of Radiotherapy is Here: Siemens Healthineers Launches Accela
GlobeNewswire · 11d ago
D-Wave Quantum vs. QuantumScape: Which Moonshot Tech Stock Is a Better Buy in 2026?
Motley Fool · 12d ago
TDM Reagent Kit Market Forecasts Growth from $2.87B (2026) to $6.96B by 2032, Profiling Abbott, Roche, Danaher, Siemens Healthineers & Thermo Fisher
GlobeNewswire · 14d ago
What Does Siemens Healthineers (XTRA:SHL) New Liver Disease Collaboration Mean?
Simply Wall St. · 15d ago
Capitalize on the Therapeutic Drug Monitoring Shift: Benchmark Roche, Abbott, Siemens Healthineers, Thermo Fisher and Bio-Rad to Accelerate Revenue and Defend Market Share
GlobeNewswire · 15d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.